Calandra G B, Raupp W, Brown K R
Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486.
Scand J Infect Dis Suppl. 1987;52:15-9.
The efficacy and safety profile of imipenem/cilastatin was investigated in 94 patients with diabetes mellitus with infections of the lower extremity. Ninety-eight percent of the pathogens were susceptible to imipenem; this was higher than to other antibiotics tested. Ninety-two percent of the patients were cured (47%) or improved (45%). Bacterial eradication was achieved for 79% of the pathogens. Adverse experiences were similar to those reported previously. Imipenem-cilastatin proved to be a very effective antibiotic with a good safety profile for use in diabetic patients with lower extremity infections.
对94例患有下肢感染的糖尿病患者研究了亚胺培南/西司他丁的疗效和安全性。98%的病原体对亚胺培南敏感；这一比例高于所测试的其他抗生素。92%的患者治愈（47%）或病情改善（45%）。79%的病原体实现了细菌清除。不良事件与先前报告的相似。亚胺培南-西司他丁被证明是一种非常有效的抗生素，对患有下肢感染的糖尿病患者使用时安全性良好。
